Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Has one of the following cancers:

• Unresectable or metastatic colorectal cancer.

• Advanced and/or unresectable biliary tract cancer (BTC)

• Hepatocellular carcinoma (HCC) not amenable to locoregional therapy

• Locally advanced unresectable or metastatic gastroesophageal cancer

• Has received prior therapy for the cancer.

• Has recovered from any side effects due to previous cancer treatment

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis thatrequired steroids, or has current ILD or pneumonitis, and/or suspected ILD orpneumonitis that cannot be ruled out by standard diagnostic assessments at Screening

• Has clinically severe respiratory compromise (based on the investigator'sassessment) resulting from intercurrent pulmonary illnesses

• Has evidence of any leptomeningeal disease

• Has clinically significant corneal disease

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection